research Are Janus Kinase (JAK) Inhibitors Beneficial in the Treatment of Androgenic Alopecia?
JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
Search
for
Sort by
Research
150-180 / 430 resultsresearch JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research Functional Complexity of Hair Follicle Stem Cell Niche and Therapeutic Targeting of Niche Dysfunction for Hair Regeneration
Understanding how hair follicle stem cells work can help find new ways to prevent hair loss and promote hair growth.
research Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options
The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
STAT5 activation is crucial for starting the hair growth phase.
research Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata
Regenerative therapies show promise for treating vitiligo and alopecia areata.
research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
research The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research Therapeutic Advances in Trichology
Recent advances in hair loss treatments show significant progress.
research New Treatments for Hair Loss
Several new treatments for different types of hair loss show promise in improving patient quality of life.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry About?
People with alopecia areata may have a higher risk of blood clots.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Research Progress on the Application of Stem Cells in Hair Regeneration
Stem cells show promise for hair regrowth, but challenges remain.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Chemokine Receptor CCR5 as a Novel Target for the Treatment of Alopecia Areata
Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.